NBSE | NeuBase Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.3650 - 0.3914
52 Week Range	0.3600 - 4.44
Beta	0.98
Implied Volatility	528.27%
IV Rank	100.00%
Day's Volume	89,703
Average Volume	128,236
Shares Outstanding	3,751,590
Market Cap	1,418,101
Sector	Healthcare
Industry	Biotechnology
IPO Date	2004-05-28

Valuation
Profitability
Growth
Health
P/E Ratio	-0.02
Forward P/E Ratio	N/A
EPS	-18.60
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	37
Country	USA
Website	NBSE

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NBSE's peers: CLLS

*Chart delayed

Analyzing fundamentals for NBSE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see NBSE Fundamentals page.

Watching at NBSE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NBSE Technicals page.